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Abstract
Background: Recently, the field of gene-gene or gene-environment interaction research appears to have gained
growing interest, although it is seldom investigated in Alzheimer’s disease (AD). Hence, the current study aims to
investigate interaction effects of the key genetic and environmental risks—the apolipoprotein ε4 allele (APOE4) and
family history of late-onset AD (FH)—on AD-related brain changes in cognitively normal (CN) middle-aged and
older adults.
Methods: [11C] Pittsburg compound-B (PiB) positron emission tomography (PET) imaging as well as [18F] fluoro-2-
deoxyglucose (FDG) PET that were simultaneously taken with T1-weighted magnetic resonance imaging (MRI) were
obtained from 268 CNs from the Korean Brain Aging Study for Early Diagnosis and Prediction of AD (KBASE).
Composite standardized uptake value ratios were obtained from PiB-PET and FDG-PET images in the AD signature
regions of interests (ROIs) and analyzed. Voxel-wise analyses were also performed to examine detailed regional
changes not captured by the ROI analyses.
Results: A significant synergistic interaction effect was found between the APOE4 and FH on amyloid-beta (Aβ)
deposition in the AD signature ROIs as well as other regions. Synergistic interaction effects on cerebral glucose
metabolism were observed in the regions not captured by the AD signature ROIs, particularly in the medial
temporal regions.
Conclusions: Strong synergistic effects of APOE4 and FH on Aβ deposition and cerebral glucose metabolism in CN
adults indicate possible gene-to-gene or gene-to-environment interactions that are crucial for pathogenesis of AD
involving Aβ. Other unspecified risk factors—genes and/or environmental—that are captured by the positive FH
status might either coexpress or interact with APOE4 to alter AD-related brain changes in CN. Healthy people with
both FH and APOE4 need more attention for AD prevention.
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Background
Decades of research on sporadic late-onset Alzheimer’s
disease (AD) dementia, the most common form of de-
mentia, have shown that AD dementia is a multifactorial
disease with a wide variety of genetic and environmental
factors playing a role in the age of onset, risk, and eti-
ology [1]. Numerous heritable and inheritable risk fac-
tors have been linked with AD pathogenesis.
Nevertheless, to date, only a limited number of studies
have investigated the interaction effect between the
major risks on in-vivo AD-related brain changes which
can reflect the pathogenesis of AD. Information about
whether the major risks of AD dementia can synergistic-
ally increase AD-specific brain changes before the onset
of dementia symptoms will likely help identification of a
more urgent target population for the preventive efforts
against AD dementia.
The apolipoprotein ε4 allele (APOE4) is a major risk
factor for AD dementia and is associated with a decade
or more mean age at onset decrease in AD symptoms
[2]. Numerous studies have reported a relationship be-
tween APOE4 and AD-related brain changes such as in-
creased amyloid-beta (Aβ) deposition and decreased
glucose metabolism even in cognitively normal (CN) eld-
erly individuals, although with some inconsistencies in
the degree of effects [3–9]. Notably, functional brain ab-
normalities associated with APOE4 as identified by de-
creased cerebral glucose metabolism in the AD-related
brain regions were found in healthy volunteers even as
young as 20–39 years old [10]. Furthermore, a recent
meta-analysis has shown strong effects of APOE4 on not
only the prevalence of amyloid pathology but also the
age of onset of AD dementia [11]. Despite some incon-
sistencies, the presence of strong effects of APOE4 on
Aβ deposition and cerebral glucose metabolism has been
repeatedly and undeniably shown.
In recent years, evidence has accumulated for other
genetic and environmental factors that influence
AD-related brain changes [1]. Having a first-degree fam-
ily history of AD dementia (FH) is another well-known
risk factor for developing AD dementia and is consid-
ered to encapsulate both genetic and environmental risk
loads [12] as it not only captures heritable genetic sus-
ceptibility but also other shared dietary, psychosocial,
and somatic factors that are shown to be associated with
an individual’s risk for developing AD dementia [13–15].
Similar to APOE4, the effects of FH on AD-related brain
changes including Aβ deposition and glucose metabol-
ism are present even in CN individuals, although less
consistently [16–18].
Previous research shows that FH and APOE4 highly
co-occur [19, 20] and, conceivably, their effects on de-
veloping AD dementia may overlap. However, given that
they reflect different hereditary factors (i.e., genetic only
or both genetic and environmental), it is likely that an
interaction of the effects of FH and APOE4 exists for
AD-related brain changes such that having both FH and
APOE4 will lead to synergistic influences on AD-related
brain changes compared to when an individual has only
one of the two risk factors. Nonetheless, to the best of
our knowledge, no study has examined the synergistic
interaction effects of FH and APOE4 on AD-related
brain changes, specifically Aβ deposition and glucose
metabolism, in cognitively intact adults. In this context,
the purpose of the current study was to test the hypoth-
esis that APOE4 and FH have synergistic interaction ef-
fects on cerebral Aβ deposition and glucose metabolism
in healthy middle-aged and older adults.
Methods
Subjects
This study is a part of the Korean Brain Aging Study for
the Early Diagnosis and Prediction of AD (KBASE), an
ongoing prospective cohort study that began in 2014 de-
signed to identify novel biomarkers for AD and to ex-
plore various lifetime experiences contributing to
AD-related brain changes. The current study included
268 community-dwelling CN individuals, between 50
years and 87 years of age, who were recruited as of
March 2016. Details on the KBASE study characteristics
including recruitment have been described previously
[21]. Individuals with medical, psychiatric, and/or neuro-
logical conditions or history of conditions that may
affect brain structures or functions, such as stroke, head
trauma, depression, hydrocephalus, or focal brain lesions
on magnetic resonance imaging (MRI) were excluded.
All subjects had reliable informants available who pro-
vided corroborative information on the family history of
medical conditions, including the presence of AD de-
mentia. Subjects had a Clinical Dementia Rating of 0
and performed within the normal range relative to age-,
gender-, and education-adjusted normative means on
comprehensive neuropsychological assessments [22, 23].
The study was ethically reviewed and all participants
provided written informed consent to participate in this
study after receiving a complete description of the study,
which is approved by Seoul National University Hospital
Institutional Review Board.
Assessments
Comprehensive clinical and neuropsychological assess-
ment data were obtained from all participants based on
the KBASE assessment protocol that incorporated and
expanded upon the Korean version of the Consortium to
Establish a Registry for Alzheimer’s Disease assessment
packet (CERAD-K) [22, 24]. A detailed description of the
cognitive assessments has been previously reported [21].
Briefly, the assessments included the Mini-Mental State
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Examination in the Korean version of the CERAD assess-
ment packet (MMSE-KC), the CERAD-K verbal memory
tests, including Word List Memory, Word List Delayed
Recall, Word List Recognition, CERAD-K Constructional
Praxis, and CERAD-K nonverbal memory delayed recall,
the Trail Making Test A and B, and the Stroop Test
(Korean Golden version), Verbal Fluency Tasks (both se-
mantic and phonemic), the CERAD-K confrontational
naming test (Modified Korean version of the Boston
Naming Test), and the Wechsler Adult Intelligence
Scale-revised edition Korean version (WAIS-R-K) Digit
Span (forward and backward). Neuropsychological test
performances are presented as z scores based on age-,
gender-, and education-adjusted normative data [24].
Genomic DNA was extracted from whole blood and
APOE genotyping was performed [25]; subjects with at
least one ε4 allele were identified as APOE4 carriers. For
the majority of participants, cognitive assessments were
administered on the same day that the neuroimaging
scans were conducted; four individuals underwent cogni-
tive assessment and neuroimaging scans on different
dates where the interval was less than 1 month.
Family history of AD
Subjects and reliable informants were administered a
semistructured interview by trained psychiatrists or a
registered nurse to gather detailed information of any
family history of dementia. Participants were asked: 1) if
any of their birth parents, natural grandparents, siblings
sharing parents, or other relatives had dementia and/or
other type of neurological diseases; 2) if so, what was the
diagnosis of the affected relative and the age of onset; 3)
whether or not the affected family member is deceased;
and 4), if deceased, what was the age at death.
Positivity of FH was determined if at least one
first-degree relative (parent or sibling) had AD onset at
65 years of age or older and whose diagnosis had been
made by a certified clinician. If formal diagnosis for a par-
ent was unavailable due to their old age or age at death
that preceded implementation of the established criteria
in hospital, participants were asked additional questions
to determine if their parent exhibited the symptoms of
AD dementia such as cognitive and functional decline
consistent with the criteria in the absence of other known
causes that could preclude an AD diagnosis; if sufficient
information was gathered and findings were deemed con-
sistent with a diagnosis of AD, these subjects were also
identified as FH-positive (FH+). If none of the first-degree
relatives was identified as having AD dementia, subjects
were classified as FH-negative (FH–).
Amyloid-beta imaging
All subjects underwent three-dimensional [11C] Pittsburg
compound B (PiB) positron emission tomography (PET)
imaging simultaneously taken with T1-weighted MRI at
3.0 T using a Biograph mMR (PET-MR) scanner
(Siemens, Washington DC, USA). Preprocessing steps
were performed using Statistical Parametric Mapping 12
(SPM12) (see Additional file 1: Methods for more detail).
Spatial normalization processes were performed on
PiB-PET data using Statistical Parametric Mapping 12
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12/) (SPM12)
implemented in Matlab 2014a (Mathworks, MA). Static
PiB-PET images were coregistered to individual T1 struc-
tural images, and transformation parameters for spatial
normalization of individual T1 images to a standard MNI
(Montreal Neurological Institute) template were calculated,
which were then used to spatially normalize the PET images
to the MNI template. The spatially normalized PiB-PET im-
ages were smoothed with an 8-mm Gaussian filter.
Additional processes were run for PiB-PET data to ob-
tain improved spatial normalization of cerebellar gray
matter, which is used as the reference region for
intensity normalization (see Additional file 1: Methods
section of the online data supplement for more detail).
The PiB retention index as the standardized uptake
value ratio (SUVR) for each region of interest (ROI) was
calculated by dividing the regional mean value by the
individual mean cerebellar uptake values. The automatic
anatomic labeling algorithm [26] and a region combining
method [27] were applied to set the ROIs to characterize
PiB retention level in frontal, lateral parietal, posterior
cingulate-precuneus (PC-PRC), and lateral temporal re-
gions. Each participant was classified as Aβ-positive if
the SUVR value was > 1.4 in at least one of the four
ROIs or as Aβ-negative if the SUVR values of all four
ROIs was ≤ 1.4 [27, 28]. For the ROI analyses, a
voxel-number weighted average SUVR of a composite
global ROI was calculated using the four ROIs
(ADPiB-ROI).
Cerebral glucose imaging
All subjects also underwent three-dimensional [18F]
fluoro-2-deoxyglucose (FDG) PET taken using the same
PET-MR scanner as the PiB-PET. The acquisition
parameters were similar to the PiB-PET procedures
(described in more detail in Additional file 1: Methods).
In terms of spatial normalization processes performed
on FDG-PET data, basic preprocessing was the same as
for PiB-PET described above. The spatially normalized
FDG-PET images were smoothed with a 12-mm Gaussian
filter. For FDG-PET images, intensity normalization was
performed on spatially normalized images using pons as
the reference region, and SUVRs were extracted for ROIs
using the standard AAL 116 atlas. For the ROI analyses, a
voxel-number weighted average SUVR of a composite
ROI (ADFDG-ROI) including middle temporal gyrus,
posterior cingulate cortex (PCC), and fusiform gyrus was
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calculated, which are the regions known to be sensitive to
metabolic changes associated with AD [17].
Statistical analysis
Analyses were performed with SPSS 23.0 and SPM12.
The APOE genotypes were coded as APOE4 carrier
(APOE4+) or noncarrier (APOE4–). Differences in clin-
ical and ROI measures between the FH groups as well as
the APOE4 groups were examined with independent
sample t tests, a general linear model (GLM), and χ2
tests. Main effects and interaction were examined in the
model, adjusting for age and gender effects. Post-hoc
tests for an interaction effect were performed using
Dunn-Sidak correction for multiple comparisons. In
addition, the APOE4 carrier status was added as a covar-
iate for main effects model of FH; likewise, the FH status
was added to covariates for the main effects model of
APOE4. Results were examined at p < 0.05.
To explore the interaction effects with more detailed re-
gional information, the GLM was used to test for regional
differences in parametric PiB and FDG SUVR images
using SPM12. Results were initially examined at p < 0.005,
uncorrected for multiple comparisons. A significant clus-
ter was identified based on a cluster correction procedure
available in the Analysis of Functional NeuroImage
(3dClustSim, version built 4 November 2016), which per-
formed 10,000 iterations of Monte Carlo simulations on
anatomical mask datasets with 1,801,748 voxels. This
method, derived from Gaussian Random Field Theory,
protects against multiple comparisons [29]. The cluster
size threshold to achieve correction for multiple compari-
sons at p < 0.05 was calculated to be k > 1062 voxels.
Results
Participant characteristics
Demographic characteristics are shown in Table 1. Of
the 268 study participants, 51 (19%) had at least one
first-degree family member with a history of late-onset
AD. Each participant was identified into one of the four
groups: FH–APOE4–, FH+APOE4–, FH–POE4+, or
FH+APOE4+. There were no differences between the
groups regarding age, gender distribution, education, or
cognitive functioning. The total allele frequency of
APOE4 in this cohort was 9%, which is consistent with a
Table 1 Subject characteristics by family history and APOE4 groups
FH–APOE4– FH+APOE4– FH–APOE4+ FH+APOE4+ P
n 180 38 37 13
Age (years), mean (SD) 68.2 (8.2) 65.2 (9.5) 69.6 (9.4) 68.2 (9.5) 0.41
Gender, female/male (% female) 97/83 (53.9) 15/23 (39.5) 20/17 (54.1) 6/7 (46.2) 0.12
Education (years), mean (SD) 11.9 (4.9) 13.4 (4.1) 11.0 (4.1) 12.2 (4.4) 0.15
APOE4 dosage, n of ε4/ε4 (%) 0 (0) 0 (0) 0 (0) 2 (15)
MMSE (raw score), mean (SD) 27.0 (2.4) 27.5 (2.4) 26.2 (2.9) 27.3 (2.5) 0.11
Neuropsychological test performance (z score, mean (SD))
Immediate Verbal Memory Free Recall 0.88 (0.96) 0.86 (0.98) 0.60 (1.02) 0.81 (0.73) 0.46
Delayed Verbal Memory Free Recall 0.41 (0.87) 0.54 (0.89) 0.29 (0.90) 0.53 (0.62) 0.60
Delayed Verbal Memory Recognition 0.19 (0.78) 0.28 (0.65) −0.003 (0.84) 0.27 (0.69) 0.40
Delayed Nonverbal Memory 0.33 (0.92) 0.49 (0.74) 0.05 (0.82) 0.45 (0.58) 0.14
Semantic Fluency 0.30 (1.12) 0.51 (1.18) −0.09 (0.80) 0.75 (1.58) 0.05
Confrontational Naming 0.52 (0.89) 0.65 (0.63) 0.35 (0.87) 0.87 (0.58) 0.22
Constructional Praxis −0.04 (0.93) 0.21 (0.66) −0.08 (1.13) −0.10 (1.04) 0.46
Stroop Color-Word 0.23 (1.04) 0.45 (0.91) −0.001 (0.76) 0.27 (0.91) 0.27
Trail Making Test A 0.65 (1.93) 1.03 (0.46) 0.48 (1.91) 0.85 (0.50) 0.54
Trail Making Test Ba 0.89 (1.04) 1.40 (0.85) 0.94 (1.14) 0.96 (0.73) 0.11
Digit Span Forward 0.36 (1.07) 0.52 (0.90) −0.04 (0.98) 0.58 (0.92) 0.08
Digit Span Backward 0.12 (1.23) 0.52 (1.34) −0.24 (0.86) 0.38 (1.81) 0.06
Amyloid-beta positive, n (%) 19 (11) 5 (13) 7 (19) 5 (38)* 0.03
APOE4 apolipoprotein ε4 allele, APOE4+ APOE4 carrier, APOE4– APOE4 noncarrier, FH parental or sibling (first-degree relative) family history of late-onset AD (age of
onset ≥ 65 years), FH+ positive FH, FH– negative FH, MMSE Mini-Mental State Examination, SD standard deviation
a35% of FH–APOE4–, 24% of FH+APOE4–, 59% of FH–APOE4+, and 38% of FH+APOE4+ did not complete the Trail Making Test B due to cognitive reasons,
participation refusal, or illiteracy
*Significantly different from the other groups based on post-hoc analyses, multiple comparisons corrected (P = 0.0067). Homozygote APOE4 carriers were not
among the five amyloid-beta-positive individuals
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previous report on APOE polymorphism among Koreans
[30]. There were two APOE4 homozygote carriers in the
entire sample, both of whom were FH+. The proportion
of Aβ-positive subjects was significantly higher in the
FH+APOE4+ group than the other groups.
Independent association of FH and APOE4 on cerebral
amyloid deposition
Significant differences between FH– and FH+ were found
for the ADPiB-ROI (Additional file 1: Table S3
(Model-A)) and remained the same when the effect was
additionally adjusted for APOE4 status (Fig. 1a;
Additional file 1: Table S3 (Model-B)).
Significant differences in Aβ deposition levels were
found in the ADPiB-ROI between the APOE4
+ and
APOE4– groups (Additional file 1: Table S3 (Model-C)).
Significant differences remained the same when FH sta-
tus was added as a covariate (Fig. 1b; Additional file 1:
Table S3 (Model-D)). Overall, PiB retention was higher
in FH+ compared with FH– and in APOE4+ compared
with APOE4–.
Independent association of FH and APOE4 on cerebral
glucose metabolism
There were no significant differences found in the
ADFDG-ROI between the FH groups (Additional file 1:
Table S3 (Model-A)) or the APOE4 groups (Additional file
1: Table S3 (Model-C)). Results remained the same when
APOE4 status was added as a covariate (Fig. 1c; Additional
file 1: Table S3 (Model-B)) or when FH status was added as
a covariate (Fig. 1d; Additional file 1: Table S3 (Model-D)).
FH-APOE4 interaction effects: ROI analyses
A significant FH-APOE4 interaction effect was found for
the ADPiB-ROI (F = 11.51, p < 0.001, R
2 = 0.112) in
addition to significant main effects of FH and APOE4
(Additional file 1: Table S1); the FH+APOE4+ group
showed significantly higher Aβ deposition compared
with the other groups (Fig. 1e). However, there were no
main or interaction effects on regional cerebral glucose
metabolism (rCMglc) between FH and APOE4 (Fig. 1f;
Additional file 1: Table S1). The interaction effects
remained significant when two APOE4 homozygote in-
dividuals were excluded (Additional file 1: Table S6).
FH-APOE4 interaction effects: voxel-wise analyses
Voxel-wise analyses were conducted between the FH+A-
POE4+ group and the other groups to further explore
detailed brain regions showing the interaction effects on
Aβ deposition and rCMglc. Compared with FH+A-
POE4–, FH+APOE4+ showed increased Aβ deposition in
the left postcentral gyrus, left superior frontal gyrus, and
left precuneus (Fig. 2a); compared with FH–APOE4+,
FH+APOE4+ showed increased Aβ deposition in the left
postcentral and supramarginal gyri and left superior
frontal gyrus (Fig. 2b); and compared with FH–APOE4–,
FH+APOE4+ showed increased Aβ deposition in the left
middle frontal and temporal gyri, right inferior parietal
lobule, left postcentral gyrus, and left posterior cingulate
gyrus (Fig. 2c). There were no regions in any of the com-
parisons where FH+APOE4+ showed lower Aβ depos-
ition levels (Additional file 1: Table S4).
Although there were no significant interaction effects
of FH and APOE4 on rCMglc found from the ROI ana-
lyses, voxel-wise analyses were conducted for explorative
purposes since subtle changes in CN adults may not
have been captured by the ADFDG-ROI. Compared with
FH+APOE4–, FH+APOE4+ showed decreased rCMglc in
the right entorhinal area and left hippocampus (Fig. 3a);
compared with FH–APOE4+, FH+APOE4+ showed de-
creased rCMglc in the right entorhinal area and inferior
temporal gyrus (Fig. 3b); and compared with FH–A-
POE4–, FH+APOE4+ showed decreased rCMglc in the
right entorhinal area (Fig. 3c). There were no regions
with significant differences in any of the comparisons
where FH+APOE4+ showed hypermetabolism compared
with the other groups (Additional file 1: Table S4).
Discussion
The present study examined whether APOE4 and FH
have synergistic interaction effects on cerebral Aβ de-
position and glucose metabolism in healthy middle-aged
and older adults. The most notable finding was a signifi-
cant increase in Aβ deposition if an individual was an
APOE4 carrier with a positive family history for AD.
While the synergistic interaction effect of FH and
APOE4 on cerebral glucose metabolism was not found
in the ROI analyses, voxel-wise analyses revealed that
the synergistic interaction effect on glucose metabolism
was in fact present in the temporal regions, including
(See figure on previous page.)
Fig. 1 Mean PiB retention and FDG uptake SUVRs. a ADPiB-ROI between FH
– and FH+. b ADPiB-ROI between APOE4
– and APOE4+. c ADFDG-ROI between
FH– and FH+. d ADFDG-ROI between APOE
– and APOE+. e Interaction effect of FH and APOE on PiB retention. f Interaction effect of FH and APOE on FDG
uptake. The green shaded area in e denotes below the PiB SUVR threshold of 1.4. Error bars indicate standard error. *P< 0.05; **significant difference in the
post-hoc analyses adjusted for multiple comparisons using Dunn-Sidak correction (PB< 0.0085). Aβ amyloid beta, APOE4 apolipoprotein ε4 allele, APOE4+
APOE4 carriers, APOE4– APOE4 noncarriers, FDG [18F] fluoro-2-deoxyglucose, FH family history of Alzheimer’s disease, FH+ individuals with FH, FH–
individuals without FH, L left hemisphere, PiB [11C] Pittsburg compound B, R right hemisphere, SUVR standardized uptake value ratio




Fig. 2 (See legend on next page.)
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the hippocampi. To the best of our knowledge, there is
no previous study examining the interaction effects of
APOE4 and FH on both Aβ deposition and rCMglc.
A body of literature devoted to investigating the gen-
etic risks of AD has largely focused on either APOE4 or
FH. The current findings on the interaction effects of
FH and APOE4 on Aβ deposition and rCMglc further
delineate the nature of the relationship between the two
risk factors on signature AD brain changes. As can be
inferred from the interaction effects, differences in the
proportions of FH+ individuals included in the study
samples may account, at least in part, for varied magni-
tudes of the effects of APOE4 reported in the literature.
Conceivably, the commonly reported effects of APOE4
on AD brain biomarkers in the literature may actually
be the effects seen in FH+APOE4+ compared with other
groups. A similar argument can be made regarding the
investigations of the effects of FH on AD brain bio-
markers since the effects of FH were only seen in
APOE4 carriers. Given the significant synergistic inter-
action effect, a simple application of statistical adjust-
ment to achieve independency of the effects of either
one of the risk factors may be misrepresenting.
A question arises as to the role played by a family his-
tory of AD in APOE4 carriers. The results from the
current study strongly suggest that the APOE4 carriers
with a family history of AD are more susceptible to
alterations of the signature AD brain biomarkers before
the onset of any cognitive symptoms. A positive family
history status may represent other susceptibility genes that
are either coexpressed or interacting with APOE4. It has
been posited that gene-gene interactions account for
much of the unexplained variances in AD status [31] and
that these interactions are widespread and common [32].
For example, clusterin (CLU; involved in AD pathogenesis
directly by influencing Aβ aggregation and clearance [33,
34]) is found to interact with APOE4 [35, 36]. Bridging in-
tegrator 1, whose role is implicated in tauopathy [37], is
thought to interact with the CLU [38]. In addition to the
known genetic risks for AD possibly interacting with each
other, there is a possibility that FH+ is capturing additional
genetics that are considered unrelated to AD but interact
with the AD genetic risks. Delineation of the role of genet-
ics in the diagnosis and risk prediction in late-onset AD is
complicated since up to 75% of APOE4 carriers do not de-
velop AD and up to 50% of individuals with AD are
APOE4 noncarriers [39, 40]. A twin study that examined
genetic and environmental influences on AD reported that
additive genetic influences explain 79% of the variance in
the AD phenotype as opposed to 21% explained by non-
shared environmental influences; when shared environ-
mental influences were added to the analysis model,
however, the variance in the AD phenotype explained by
additive genetic influences changed to 58%, and 42% of
the variance was explained by environmental influences
(both shared (19%) and nonshared (23%)) [12]. Further-
more, a more recent study using the Alzheimer’s Disease
Genetics Consortium data and Genome-wide Complex
Trait Analysis method reported that 53.24% of phenotypic
variance was explained by genetics [41]. Given that
(See figure on previous page.)
Fig. 2 Regions showing significant differences in Aβ deposition from voxel-wise analyses. a FH+APOE4+ compared with FH+APOE4–. b
FH+APOE4+ compared with FH–APOE4+. c FH+APOE4+ compared with FH–APOE4–. A anterior, APOE4 apolipoprotein ε4 allele, APOE4+ APOE4
carriers, APOE4– APOE4 noncarriers, FH family history of Alzheimer’s disease, FH+ individuals with FH, FH– individuals without FH, L left
hemisphere, P posterior, R right hemisphere
A B C
Fig. 3 Regions showing significant difference in cerebral glucose metabolism from voxel-wise analyses. a FH+APOE4+ compared with FH+APOE4–. b
FH+APOE4+ compared with FH–APOE4+. c FH+APOE4+ compared with FH–APOE4–. APOE4 apolipoprotein ε4 allele, APOE4+ APOE4 carriers, APOE4–
APOE4 noncarriers, FH family history of Alzheimer’s disease, FH+ individuals with FH, FH– individuals without FH, L left hemisphere, R right hemisphere
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environmental factors likely can explain the variance un-
accounted for by genetic risks, involvement of a family’s
shared environments (captured by FH+) needs to be con-
sidered carefully as they may interact with APOE4 and
other genetic risks. Shared environmental factors, which
are seldom reported in association with Aβ, include a
family’s socioeconomic status, place of living (e.g., urban
versus rural), lifestyle or dietary habits, parents’ educa-
tional attainment and intellectual environment, and ex-
posure to pollution [42–46]. Cognitive activity during the
early life stage, for example, has been found to be associ-
ated with reduced neurodegeneration in AD signature re-
gions in later life [47]. Although the abovementioned
environmental factors may not individually show strong
effects on AD, a combination of the environmental factors
with APOE4 or other genetic risks may exhibit meaningful
influences on AD neuropathology.
While independent main effects of APOE4 and FH were
observed on Aβ deposition, there were no differences in
cerebral glucose metabolism between the FH groups or
the APOE4 groups in the brain regions typically affected
in clinical AD patients in the current sample of cognitively
normal elderly whose degree of degeneration is not yet
progressed enough to be detected. In line with the find-
ings by Lowe et al. [5] who showed that most of the
APOE4-related differences in hypometabolism are medi-
ated by amyloid accumulation, hypometabolism associated
with APOE4 or FH in the AD signature regions in the
current sample was only observed in individuals with high
Aβ deposition (Additional file 1: Figure S1, Table S5),
suggesting that the effects of APOE4 or FH on cerebral
glucose metabolism only begin to show when the disease
is progressed. Moreover, the hypometabolic pattern
observed, particularly in the medial temporal regions, in
association with FH+ and APOE4+ status (Fig. 3) is note-
worthy given that these regions are where phosphorylated
tau (p-tau) pathology is first to develop prior to accumula-
tion of neurofibrillary tangles [8]. Taken together, the
current cross-sectional observation in the CN likely re-
flects early observation of abnormal Aβ biomarkers prior
to the onset of changes in glucose metabolism in the AD
signature regions, which supports the amyloid patho-
logical cascade model [48].
A strength of the current study is that the study partici-
pants were recruited from the community and that the
sample includes a large number of APOE4+ and FH+ indi-
viduals despite relatively lower proportions (18% and 19%,
respectively) compared with previous studies (24–43% and
up to 66%, respectively) [5, 6, 8, 9, 16, 18]. The studies
based on the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) data, for instance, frequently recruited from family
members of AD patients such that the samples included a
large proportion of FH+ individuals, and these samples in-
cluded a large proportion of Aβ-positive CN individuals
(e.g., 47%) [1, 5, 49], which is considerably higher than the
current sample (13%). The current findings on the inde-
pendent effects of APOE4 and FH on Aβ deposition and
glucose metabolism are therefore relatively robust from dif-
ferences in the proportions of APOE4+ or the number of
FH+ individuals included in the total sample.
Similar to previous studies on FH, steps were taken to
ensure that AD diagnosis in the subjects’ parents was ac-
curate, such as including only the subjects whose par-
ent’s AD diagnosis was made by a clinician according to
the established criteria. Also, in a few cases where par-
ents were deceased before formal diagnosis was available
in clinics (i.e., parents of our old-old participants), a
thorough interview was conducted with family members
by a psychiatrist with expertise in dementia research to
sufficiently address the inclusion/exclusion criteria of
the AD diagnosis. Nonetheless, our cohort may have in-
cluded a few participants whose parents did not have
AD but instead had other types of dementia since the in-
formation obtained regarding those parents without a
formal diagnosis is subject to recall bias. In the future,
an investigation into possible protective effects of the
APOE ε2 allele will allow further understanding of its
role in the interaction effect of APOE and FH.
Conclusions
The current study was the first attempt to elucidate the
interaction effects between FH and APOE4 on cerebral
Aβ deposition and glucose metabolism in cognitively
healthy adults. The strong synergistic effects of APOE4
and FH on brain Aβ deposition and hypometabolism
that were found indicate possible gene-to-gene or
gene-to-environment interactions that are important for
the pathogenesis of AD. Such a synergistic effect also in-
dicates that individuals with both FH and APOE4 are
the population that needs more attention with regard to
preventive interventions.
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